We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Biopharma Credit Plc | LSE:BPCR | London | Ordinary Share | GB00BDGKMY29 | ORD USD0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.004 | -0.46% | 0.874 | 0.874 | 0.878 | 0.878 | 0.874 | 0.878 | 76,502 | 08:01:56 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 135.74M | 108.45M | 0.0833 | 10.56 | 1.15B |
From Apr 2019 to Apr 2024
TIDMBPCR
RNS Number : 6203I
BioPharma Credit PLC
12 August 2019
12 August 2019
BIOPHARMA CREDIT PLC
("The Company")
NOTICE OF INTERIM RESULTS
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, will announce its audited Half Year Results for the period ending 30 June 2019, on Wednesday 4 September 2019.
A management presentation will be held at 09:30am at Buchanan, 107 Cheapside, EC2V 6DN. A conference call facility will also be available.
To confirm your attendance, or request conference call details, RSVP to biopharmacredit@buchanan.uk.com.
-Ends-
Enquiries
BioPharma Credit PLC
via Link Company Matters Limited
Company Secretary
+44 (0) 1392 477 500
Buchanan
+44 (0)20 7466 5000
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NOREKLFBKVFFBBK
(END) Dow Jones Newswires
August 12, 2019 02:00 ET (06:00 GMT)
1 Year Biopharma Credit Chart |
1 Month Biopharma Credit Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
